Latest Conference Articles

November 5th 2020, 6:54pm

PER® Chemotherapy Foundation Symposium (CFS)

There is still a great deal to learn about the optimal use of BRAF-targeted therapy, as well as immunotherapy, in the adjuvant setting for patients with melanoma.

November 5th 2020, 4:23pm

PER® Chemotherapy Foundation Symposium (CFS)

PARP inhibitors have emerged as a promising therapeutic target in prostate cancer at the 38th Annual CFS® virtual conference.

November 4th 2020, 8:10pm

PER® Chemotherapy Foundation Symposium (CFS)

An explosion of therapeutic options for chronic lymphocytic leukemia has resulted in challenging questions about sequencing therapies for patients who progress after frontline treatment with little data to guide optimal therapy selection.

November 4th 2020, 7:45pm

PER® Chemotherapy Foundation Symposium (CFS)

Frontline treatment decisions for patients with follicular lymphoma can be guided by a general framework; the choice of therapy is often based on several factors such as indications of therapy, bulk of disease, comorbidities, and toxicity.

November 4th 2020, 4:08pm

PER® Chemotherapy Foundation Symposium (CFS)

The treatment landscape for multiple myeloma is poised to enter a new era of innovation with the development of therapies that target B-cell maturation antigen, which is highly expressed on plasma and MM cells.

October 29th 2020, 4:46pm

SMR Congress

With an estimated 5-year survival rate of 50% and an ongoing issue of resistance, next steps with immunotherapy in melanoma will focus on stratifying patients, personalizing therapy, and refining localized regimens.

October 29th 2020, 2:59pm

SMR Congress

The addition of anti–PD-1/PD-L1 to combination BRAF and MEK inhibition has been shown to improve progression-free survival and duration of response in patients with BRAF-mutated melanoma, suggesting potential to overcome resistance to targeted approaches.

October 28th 2020, 11:00pm

SMR Congress

Jason J. Luke, MD, FACP, discusses the importance of BRAF in melanoma.

October 28th 2020, 11:00pm

SMR Congress

Jeffrey S. Weber, MD, PhD, discusses the results of the phase 3 COMBI-AD trial with dabrafenib plus trametinib in patients with resected, stage III BRAF V600E/K–mutant melanoma.

October 3rd 2020, 9:32pm

NANETS Symposium

XmAb18087 demonstrated a disease control rate of 43% across dose levels in patients with neuroendocrine tumors and a favorable safety profile.

October 3rd 2020, 9:00pm

NANETS Symposium

The novel somatostatin analog for the Targeted Alpha-emitter Therapy 212Pb-DOTAMTATE has demonstrated early efficacy and a tolerable safety profile in a small cohort of patients with metastatic somatostatin receptor–expressing neuroendocrine tumors irrespective of location of the primary tumor.

October 3rd 2020, 6:15pm

NANETS Symposium

Aman Chauhan, MD, a medical oncologist at the University of Kentucky, discusses key recent advances in therapeutics for patients with neuroendocrine tumors, and points to the future with ongoing combination studies.

October 3rd 2020, 5:22pm

NANETS Symposium

Increasing the dosage of lanreotide autogel from every 28 days to every 14 days led to encouraging progression-free survival outcomes in patients with progressive pancreatic and midgut neuroendocrine tumors.

October 3rd 2020, 10:00am

NANETS Symposium

Jonathan Strosberg, MD, discusse​s retreatment with Lutathera in advanced neuroendocrine tumors.

October 3rd 2020, 10:00am

NANETS Symposium

Aman Chauhan, MD, a medical oncologist at the University of Kentucky, discusses the role of ​Lutathera in neuroendocrine tumors.

October 2nd 2020, 10:09pm

NANETS Symposium

Marianne Pavel, MD, discusses the progression-free survival of patients with pancreatic and midgut neuroendocrine tumors who are treated with lanreotide autogel in the phase 2 CLARINET FORTE trial.

October 2nd 2020, 9:42pm

NANETS Symposium

Investigators are evaluating the combination of telotristat ethyl and Lutathera with a goal to improve progression-free survival in patients with well-differentiated neuroendocrine tumors in a randomized, phase 2 study that was highlighted during the 2020 NANETs Virtual Symposium.

October 2nd 2020, 9:20pm

NANETS Symposium

Longer-term data demonstrated that treatment with the radiopharmaceutical Lutathera continued to show low rates of toxicity among patients with somatostatin receptor–positive neuroendocrine tumors.

October 1st 2020, 4:16pm

ESMO Congress

Brigatinib demonstrated sustained improvements in overall and intracranial progression-free survival and health-related quality of life compared with crizotinib in patients with ALK-positive advanced non–small cell lung cancer.

September 29th 2020, 4:30pm

ESMO Congress

Plinabulin was found to be a more favorable option for the prevention of chemotherapy-induced neutropenia compared with pegfilgrastim during the coronavirus disease 2019 pandemic.